Cannabis Use, a Self-Management Strategy Among Australian Women With Endometriosis: Results From a National Online Survey

Sinclair et al. ·Journal of Obstetrics and Gynaecology Canada Impact 0.9

Gemischt GRADE Niedrig 66 Zitate

Stichproben = 484 Pat.

DauerOktober bis Dezember 2017

EndpunktSelbstberichtete…

Verblindungn.a.

DesignKohortenstudie

Kernaussage

Frauen berichteten hohe Selbsteinschätzung der Schmerzreduktion (7,6/10) und Verbesserung von Schlaf sowie Übelkeit/Erbrechen, mit 56% die Pharmaka um mindestens die Hälfte reduzierten; Nebenwirkungen waren selten (10%) und gering.

Zusammenfassung

n=484 australische Frauen mit Endometriose, 13% berichten Cannabis-Selbstmedikation zur Schmerzkontrolle; deskriptive Umfrage ohne kontrollierte Outcomes, Wirksamkeit nicht quantifiziert.

PopulationAustralische Frauen mit chirurgisch bestätigter Endometriose, Alter 18–45 Jahre, n=484 (davon 13% Cannabis-Nutzerinnen, n≈63)

InterventionSelbst-administriertes Cannabis zur Symptomkontrolle (Applikationsform nicht spezifiziert, überwiegend illizit erworben)

OutcomeSelbstberichtete Schmerzreduktion 7,6/10; 56% reduzierten pharmazeutische Medikation um ≥50%; Verbesserungen bei Schlaf und Übelkeit; Nebenwirkungen selten (10%) und gering

Vertrauen in die Evidenz

Niedrig

Zweite von vier GRADE-Stufen, die Effektschätzung ist begrenzt verlässlich.

Qualitätsprofil

Größe ★★★★★

Verblindung —

Effektstärke Gemischt

Zitate / Jahr ★★★★★

Autoren

Sinclair J, Smith C A, Abbott J et al.

DOI 10.1016/j.jogc.2019.08.033↗

Design: Kohortenstudie

Abstract

Objective: This study sought to determine the prevalence, tolerability, and self-reported effectiveness of cannabis in women with endometriosis. Methods: A cross-sectional online survey was conducted between October and December 2017. Recruitment targeted women with endometriosis through social media postings from endometriosis advocacy groups. Women aged 18 to 45, living in Australia, and with surgically confirmed endometriosis were eligible to participate. Survey questions investigated the types of self-management used, change in symptoms or medication use, costs, and adverse events. Results: A total of 484 responses were included for analysis, with 76% of the women reporting the use of general self-management strategies within the last 6 months. Of those using self-management, 13% reported using cannabis for symptom management. Self-reported effectiveness in pain reduction was high (7.6 of 10), with 56% also able to reduce pharmaceutical medications by at least half. Women reported the greatest improvements in sleep and in nausea and vomiting. Adverse effects were infrequent (10%) and minor. Conclusion: Australian law currently requires legal medicinal cannabis use to follow specific, regulated pathways that limit prescription by this method; however, self-reported illicit use of cannabis remains relatively common in Australian women with endometriosis. Women report good efficacy of cannabis in reducing pain and other symptoms, with few adverse effects reported. Further clinical research is warranted to determine the effectiveness of cannabis in managing endometriosis symptoms. In locations where medicinal cannabis is more accessible, there remains a paucity of evidence for its clinical efficacy with endometriosis-associated symptoms. Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel